Literature DB >> 11480589

Expression of vascular endothelial growth factor in a human hemangiosarcoma cell line (ISO-HAS).

Y Amo1, M Masuzawa, Y Hamada, K Katsuoka.   

Abstract

Vascular endothelial growth factor (VEGF), in addition to being a specific mitogen of endothelial cells in vitro, is also known to induce angiogenesis in vivo. These functions suggest that VEGF may play an important role in the growth of hemangiosarcomas. Previous studies have demonstrated the expression of VEGF and its receptors, flt-1 or KDR/flk-1, in hemangiosarcomas by immunohistochemical staining and in situ hybridization. In the present study, however, we demonstrated that tumor cells of the hemangiosarcoma cell line ISO-HAS express mRNA of VEGF and its two receptors, flt-1 and KDR, and secrete VEGF protein. VEGF mRNA expression and protein secretion were found to be enhanced by phorbol 12-myristate 13-acetate. In addition, we demonstrated that ISO-HAS cells respond to recombinant human VEGF165 with a dose-dependent up-regulation of cell proliferation and growth. These results suggest that the VEGF-VEGF receptor system plays a role in proliferation and growth of hemangiosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11480589     DOI: 10.1007/s004030100228

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  5 in total

1.  Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.

Authors:  Margaret von Mehren; Cathryn Rankin; John R Goldblum; George D Demetri; Vivien Bramwell; Christopher W Ryan; Ernest Borden
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

Review 2.  Angiosarcomas and taxanes.

Authors:  Nicolas Penel; Amélie Lansiaux; Antoine Adenis
Journal:  Curr Treat Options Oncol       Date:  2007-12-08

3.  Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.

Authors:  Sandra P D' Angelo; Michelle R Mahoney; Brian A Van Tine; Douglas R Adkins; Maria T Grosse Perdekamp; Mercedes M Condy; Jason J Luke; Eliza Woodward Hartley; Cristina R Antonescu; William D Tap; Gary K Schwartz
Journal:  Cancer Chemother Pharmacol       Date:  2015-02-12       Impact factor: 3.333

Review 4.  A review of soft-tissue sarcomas: translation of biological advances into treatment measures.

Authors:  Ngoc T Hoang; Luis A Acevedo; Michael J Mann; Bhairavi Tolani
Journal:  Cancer Manag Res       Date:  2018-05-10       Impact factor: 3.989

5.  In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.

Authors:  Alex A Pyuen; Travis Meuten; Barbara J Rose; Douglas H Thamm
Journal:  PLoS One       Date:  2018-07-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.